1. Analyst View
2. Research Methodology
3. Immuno-Oncology: Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending in Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
4.2.1 Patent Expiry of Top-Selling Drugs
4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment
4.2.3 Sky-High Development Costs of Cancer Immunotherapies
4.2.4 High Cost of Treatment
4.2.5 Lack of Awarenes
4.3 Opportunities
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increase in Survival
4.3.3 CAR-T Therapies: The Future of Cancer Care
4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. Global Immuno-Oncology Market Outlook 2022
6. Global Immuno-Oncology Market, by Product Class
6.1 Monoclonal Antibodies (mAbs)
6.1.1 Naked Monoclonal Antibodies
6.1.1.1 Rituxan (Rituximab)
6.1.1.2 Avastin (Bevacizumab)
6.1.1.3 Herceptin (Trastuzumab)
6.1.2 Conjugated Monoclonal Antibodies
6.1.2.1 ADCETRIS (Brentuximab vedotin)
6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
6.1.3 Bispecific Monoclonal Antibodies
6.1.3.1 Blincyto (Blinatumomab)
6.1.4 Others
6.2 Therapeutic Vaccines
6.2.1 Provenge
6.3 Immune Checkpoint Inhibitors
6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
6.3.1.1 Yervoy (Ipilimumab)
6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death-1 and Programmed Death-Ligand 1)
6.3.2.1 Opdivo (Nivolumab)
6.3.2.2 Keytruda (Pembrolizumab)
6.4 Others
7. Global Immuno-Oncology Market, By Major Indications
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. Global Immuno-Oncology Market, By Geography
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. Trends & Developments
9.1 Lucrative Investment Trends
9.2 Emergence of Targeted and Combination Therapies
9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry
11. Pipeline Analysis of Immuno-Oncology
12. Competitive Landscape
12.1 Share of Major Players
13. Key Players Analysis
13.1 F. Hoffmann-La Roche AG
13.2 Celgene Corporation
13.3 Bristol-Myers Squibb
13.4 Merck & Co., Inc.
13.5 Novartis
13.6 AstraZeneca Plc
13.7 Pfizer Inc
13.8 Eli Lilly and Company
13.9 Johnson & Johnson
13.10 Amgen Inc.